![Claudio Alì](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Claudio Alì
Società | Posizione | Inizio | Fine |
---|---|---|---|
BMG Pharma SpA
![]() BMG Pharma SpA Household/Personal CareConsumer Non-Durables BMG Pharma SpA is a pharmaceutical company based in Milan, Italy. The Italian company specializes in the development and international partnership of bio-pharmaceutical products. The company focuses on the progress of oral care, dermatology, and dietary supplements. BMG Pharma is committed to sustainability, diversity, and inclusion in the workplace. BMG Pharma has developed the hyaluromimethic® technology, which they believe is a fundamental value. The company has registered 36 innovative products and launched 37 on the international market. Recently, BMG Pharma has signed an agreement with HTL Biotechnology for the production of the functional ingredient at the base of the patented hyaluromimethic®. The company was founded in 2011 by Marco Mastrodonato and Roberto Bianchi, with Marco Mastrodonato serving as the CEO since then. | Presidente | - | - |
Storia della carriera di Claudio Alì
Statistiche
Distribuzione geografica
Italia | 2 |
Posizioni
Chairman | 1 |
Settori
Consumer Non-Durables | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
BMG Pharma SpA
![]() BMG Pharma SpA Household/Personal CareConsumer Non-Durables BMG Pharma SpA is a pharmaceutical company based in Milan, Italy. The Italian company specializes in the development and international partnership of bio-pharmaceutical products. The company focuses on the progress of oral care, dermatology, and dietary supplements. BMG Pharma is committed to sustainability, diversity, and inclusion in the workplace. BMG Pharma has developed the hyaluromimethic® technology, which they believe is a fundamental value. The company has registered 36 innovative products and launched 37 on the international market. Recently, BMG Pharma has signed an agreement with HTL Biotechnology for the production of the functional ingredient at the base of the patented hyaluromimethic®. The company was founded in 2011 by Marco Mastrodonato and Roberto Bianchi, with Marco Mastrodonato serving as the CEO since then. | Consumer Non-Durables |
- Borsa valori
- Insiders
- Claudio Alì
- Esperienza